Vetter has announced its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany, marking a significant milestone in the company’s long-term global growth strategy.
Construction is scheduled to begin in the second quarter of 2026. Initially, approximately €480m has been allocated for the first construction phase of the new commercial production plant.
Operations are expected to commence in 2031.
The Contract Development and Manufacturing Organisation (CDMO) acquired the approximately 95-acre industrial property in the city of Saarlouis at the end of 2024, stating that the location was chosen after careful strategic investment considerations and was supported by significant regional advantages.
Vetter has said that it sees the potential to create up to 2000 jobs in the long term.
The European Commission has approved up to €47m of state aid for this extensive project.
"With the construction of our new production facility in Germany, we continue on our path to sustainable growth."
"Long-term success derives from striking the right balance between stability and expansion," emphasises Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family.
"With our investments in the state of Saarland, only a five-hour drive away from our headquarters in Ravensburg, we are strengthening our commitment to Germany’s economic landscape while reaffirming our engagement as a strategic partner to the global pharmaceutical market."
To meet growing customer demand and increasing market requirements, the company is investing in its existing sites in Germany, Austria and the United States.
With its newly planned commercial site, Vetter will significantly expand its production capacity.
In parallel, the company has recently begun construction on a new clinical production site in Des Plaines, Illinois, USA.
This new aseptic manufacturing facility emphasises Vetter’s commitment to providing high-quality services and drug products during early clinical development.